# A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

> **NCT07285148** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Pearl Biotechnology Limited Liability Company** · enrollment: 253 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- EGFR Mutation
- Metastatic Lung Cancer
- MET Alteration

## Interventions

- **DRUG:** ANS014004 + PLB1004
- **DRUG:** ANS014004 + Osimertinib

## Key facts

- **NCT ID:** NCT07285148
- **Lead sponsor:** Beijing Pearl Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 253 (ESTIMATED)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285148, "A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07285148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*